WHAT IS CLAIMED IS:

1. A multivalent immunogenic composition comprising:

polysaccharide-protein conjugates,

wherein each of the polysaccharide-protein conjugates includes *Streptococcus pneumoniae*-derived capsular polysaccharides of different serotypes conjugated to a carrier protein, and

the *Streptococcus pneumoniae*-derived capsular polysaccharides ~~include~~are of

~~a) capsular polysaccharides of one or more serotypes selected from the group consisting of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, and~~

~~b) capsular polysaccharides of one or more serotypes selected from the group consisting of serotypes 10A, 11A, 15B, 22F, 23A, and 35B~~

19 different serotypes including serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 10A, 11A, 14, 15B, 18C, 19A, 19F, 22F, 23A, 23F, and 35B, wherein the serotypes 4, 15B and 19A are not hydrolyzed.

~~2. The multivalent immunogenic composition of claim 1, wherein the a) capsular polysaccharides are thirteen serotypes consisting of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.~~

~~3~~2. The multivalent immunogenic composition of claim 1, wherein the carrier protein is any one selected from the group consisting of a diphtheria toxoid, a tetanus toxoid, a whooping cough toxoid, a cholera toxoid, an *E. coli*-derived inactivated toxin, a *Pseudomonas aeruginosa*-derived inactivated toxin, and a bacterial outer membrane protein (OMP).

4~~1~~3. The multivalent immunogenic composition of claim ~~1~~2, wherein the diphtheria toxoid is any one selected from the group consisting of CRM_{197}, CRM_{173}, CRM_{228}, and CRM_{45}.

~~5~~4. The multivalent immunogenic composition of claim 1, wherein a method of conjugating the capsular polysaccharides and the carrier protein is one or more selected from the group consisting of a CDAP conjugation method, a reductive amination method, and a thiol-malemide method.

~~6~~5. The multivalent immunogenic composition of claim 1, further comprising:

an adjuvant.

~~7~~6. The multivalent immunogenic composition of claim ~~6~~5, wherein the adjuvant is an aluminum salt.

~~8~~7. The multivalent immunogenic composition of claim ~~7~~6, wherein the aluminum salt is any one selected from the group consisting of aluminum phosphate, aluminum sulfate, and aluminum hydroxide.

~~9~~8. The multivalent immunogenic composition of claim 1, wherein the ~~multivalent immunogenic composition includes a~~ *Streptococcus pneumoniae*-derived capsular polysaccharide~~s~~ of each serotype is present in an amount of 0.1 to 100 μg.

~~10~~9. A pharmaceutical composition for inducing an immune reaction to a *Streptococcus pneumoniae* - capsular polysaccharide conjugate, comprising:

an immunologically effective amount of the multivalent immunogenic composition according to any one of claims 1 to ~~9~~8.

~~11~~10. Use of the multivalent immunogenic composition according to any one of claims 1 to ~~9~~ 8 in the manufacture of a medicament for the treatment or prevention of pneumococcus-related diseases.

~~12~~11. The use of claim ~~11~~10, wherein the medicament is to be administered to a subject in need thereof in a therapeutically or prophylactically effective amount.